Sunday, 23 June 2024

Bionomics' licensee Ironwood submits IND for anti-anxiety drug

08 November 2012 | Regulatory | By BioSpectrum Bureau

Ironwood submits IND for anti-anxiety drug on behalf of Bionomics

Ironwood submits IND for anti-anxiety drug on behalf of Bionomics

Singapore: Bionomics has been advised by its licensee Ironwood Pharmaceuticals that an Investigational New Drug (IND) application was submitted to the US FDA for a clinical trial of anti-anxiety drug candidate IW-2143.

Ironwood intends to initiate phase I studies with IW-2143 in healthy volunteers following the filing of the IND by the FDA. The initial phase I US trial is designed to further assess IW-2143's pharmacokinetics.

"Ironwood has a strong team that has developed a thorough clinical development program for IW-2143," said Dr Deborah Rathjen, CEO and MD, Bionomics. 

Preclinical studies conducted by Bionomics suggest that IW-2143 has anti‐anxiety activity and promotes neurite outgrowth. In the US alone, anxiety disorders affect 40 million Americans each year and while there are therapies available, there remains a significant unmet need. IW-2143 has the potential to fill a need in this market as an anxiety drug that may not have the sedation, withdrawal syndrome or memory impairment reported with other therapies.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account